Objective To explore the effect of Sanshen Shuxin Decoction combined with Huangqi Injection in the treatment of coronary heart disease (CHD) and its impacts on left ventricular function and Rho kinase (ROCK) expression.

Methods A total of 120 CHD patients admitted to our hospital from August 2021 to August 2023 were selected as study subjects and randomly divided into three groups, with 40 patients in each group using a random number table method. All three groups received basic treatment. On this basis, control group 1 received Sanshen Shuxin Decoction, control group 2 received Huangqi Injection, and the combined group received both Sanshen Shuxin Decoction and Huangqi Injection. The treatment effects, occurrence of angina pectoris, hemorheological parametersfibrinogen (FIB), low-shear blood viscosity, erythrocyte aggregation index, high-shear blood viscosity, blood lipid indicatorstotal cholesterol (TG), triglycerides (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), cardiac functionstroke volume (SV), cardiac output (CO), left ventricular ejection fraction (LVEF), ROCK activity, and occurrence of adverse reactions were compared among the three groups.

Results The total effective rate of treatment in the combined group was higher than that in control group 1 and control group 2 (P < 0.05). After 14 days of treatment, the frequencyof angina pectoris episodes decreased and the duration of episodes shortened in all three groups compared with before treatment, and the combined group had a lower frequency and shorter duration of angina pectoris episodes than control group 1 and control group 2 (P < 0.05). There were no statistically significant differences in the frequency and duration of angina pectoris episodes between control group 1 and control group 2 after 14 days of treatment (P>0.05). After 14 days of treatment, FIB level, erythrocyte aggregation index, low-shear blood viscosity, and high-shear blood viscosity decreased in all three groups compared with before treatment, and the combined group had lower values than control group 1 and control group 2(P < 0.05). There were no statistically significant differences in these hemorheological parameters between control group 1 and control group 2 after 14 days of treatment (P>0.05). After 14 days of treatment, TG, TC, and LDL-C levels decreased in all three groups compared with before treatment, and the combined group had lower levels than control group 1 and control group 2. HDL-C levels increased in all three groups compared with before treatment, and the combined group had higher HDL-C level than control group 1 and control group 2 (P < 0.05). There were no statistically significant differences in TG, TC, LDL-C, and HDL-C levels between control group 1 and control group 2 after 14 days of treatment (P>0.05). After 14 days of treatment, LVEF, CO, and SV increased in all three groups compared with before treatment, and the combined group had higher values than control group 1 and control group 2(P < 0.05). There were no statistically significant differences in LVEF, CO, and SV between control group 1 and control group 2 after 14 days of treatment (P>0.05). Before treatment, ROCK activity was (61.28±7.15)% in the combined group, (60.85±5.93)% in control group 1, and (60.61±6.27)% in control group 2, with no statistically significant difference among the three groups (P>0.05). After 14 days of treatment, ROCK activity decreased in all three groups compared with before treatment, and the combined group had lower ROCK activity than control group 1 and control group 2 (P < 0.05). ROCK activity was (40.18±5.03)% in the combined group, (48.24±6.29)% in control group 1, and (47.79±6.12)% in control group 2 after 14 days of treatment. There was no statistically significant difference in ROCK activity between control group 1 and control group 2 after 14 days of treatment (P>0.05). There was no statistically significant difference in the incidence of adverse reactions among the three groups (P>0.05).

Conclusion Sanshen Shuxin Decoction combined with Huangqi Injection has a significant effect in the treatment of CHD patients. It can improve patients' prognosis and ensure treatment safety, demonstrating high clinical value.